ReviewAnnals of the American Thoracic Society2020
COVID-19 Lung Injury and High-Altitude Pulmonary Edema. A False Equation with Dangerous Implications.
Review in Annals of the American Thoracic Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Case Report: High altitude, young lives: unmasking pulmonary hypertension in two unique cases.Frontiers in medicine · 2025Article
- Effect of furosemide in the treatment of high-altitude pulmonary edema.BMC pulmonary medicine · 2024Article
- Association of the C allele of rs479200 in the EGLN1 gene with COVID-19 severity in Indian population: a novel finding.Human genomics · 2024Article
- Negative pressure pulmonary edema (Review).Experimental and therapeutic medicine · 2023Review
- Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study.Molecular psychiatry · 2023Article
- Article
- High altitude Relieves transmission risks of COVID-19 through meteorological and environmental factors: Evidence from China.Environmental research · 2022Article
- Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective.Nature reviews. Cardiology · 2022Review
- Intersections between pneumonia, lowered oxygen saturation percentage and immune activation mediate depression, anxiety, and chronic fatigue syndrome-like symptoms due to COVID-19: A nomothetic network approach.Journal of affective disorders · 2022Article
- COVID-19, Cation Dysmetabolism, Sialic Acid, CD147, ACE2, Viroporins, Hepcidin and Ferroptosis: A Possible Unifying Hypothesis.F1000Research · 2022Review
- Increased ACE2, sRAGE, and Immune Activation, but Lowered Calcium and Magnesium in COVID-19.Recent advances in inflammation & allergy drug discovery · 2022Article
- Potential ofFrontiers in microbiology · 2022Article
- Forty-fifth ASPEN Presidential Address: Research in a pandemic-Why, what, how?JPEN. Journal of parenteral and enteral nutrition · 2021Article
- Coronavirus disease 2019 (COVID-19): Multisystem review of pathophysiology.Annals of medicine and surgery (2012) · 2021Review
- Host metabolic reprogramming in response to SARS-CoV-2 infection: A systems biology approach.Microbial pathogenesis · 2021Article
- The Oxygen Transport Triad in High-Altitude Pulmonary Edema: A Perspective from the High Andes.International journal of environmental research and public health · 2021Article
- Article
- COVID-19: Molecular and Cellular Response.Frontiers in cellular and infection microbiology · 2021Review
- Altitude and COVID-19: Friend or foe? A narrative review.Physiological reports · 2021Review
- Acute Kidney Injury and Early Predictive Factors in COVID-19 Patients.Frontiers in medicine · 2021Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amid efforts to care for the large number of patients with coronavirus disease (COVID-19), there has been considerable speculation about whether the lung injury seen in these patients is different than acute respiratory distress syndrome from other causes. One idea that has garnered considerable attention, particularly on social media and in free open-access medicine, is the notion that lung injury due to COVID-19 is more similar to high-altitude pulmonary edema (HAPE). Drawing on this concept, it has also been proposed that treatments typically employed in the management of HAPE and other forms of acute altitude illness-pulmonary vasodilators and acetazolamide-should be considered for COVID-19. Despite some similarities in clinical features between the two entities, such as hypoxemia, radiographic opacities, and altered lung compliance, the pathophysiological mechanisms of HAPE and lung injury due to COVID-19 are fundamentally different, and the entities cannot be viewed as equivalent. Although of high utility in the management of HAPE and acute mountain sickness, systemically delivered pulmonary vasodilators and acetazolamide should not be used in the treatment of COVID-19, as they carry the risk of multiple adverse consequences, including worsened ventilation-perfusion matching, impaired carbon dioxide transport, systemic hypotension, and increased work of breathing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.